论文部分内容阅读
目的:探讨培美曲塞联合顺铂对肺腺癌炎性因子、免疫功能的影响。方法:选择信阳市中心医院2014年1月至2015年11月82例Ⅲb期及Ⅳ期肺腺癌患者为观察对象,采用随机数字表法分为观察组和对照组各41例。观察组采用培美曲塞联合顺铂化疗,对照组采用吉西他滨联合顺铂化疗。比较两组患者近期疗效、炎性因子变化情况。结果:近期疗效:两组患者疾病缓解率、疾病控制率比较,差异无统计学意义(P>0.05);炎性因子:观察组自然杀伤性细胞(NK)、γ-干扰素(IFN-γ)明显高于对照组,白细胞介素-10(IL-10)明显低于对照组(P<0.05);不良反应:观察组白细胞减少、血小板减少、恶心呕吐、乏力等发生率明显低于对照组(P<0.05)。结论:培美曲塞联合顺铂有助于降低炎性反应,增强细胞免疫功能,改善晚期肺腺癌患者预后。
Objective: To investigate the effect of pemetrexed combined with cisplatin on the inflammatory factors and immune function of lung adenocarcinoma. Methods: Eighty-two patients with stage Ⅲb and Ⅳ lung adenocarcinoma from January 2014 to November 2015 in Xinyang Central Hospital were selected as the observation subjects and divided into observation group (41 cases) and control group (41 cases) by random number table. The observation group with pemetrexed combined with cisplatin chemotherapy, the control group with gemcitabine plus cisplatin chemotherapy. The two groups of patients with short-term efficacy, changes in inflammatory cytokines. Results: The short-term curative effect: The disease remission rate and disease control rate in the two groups were not significantly different (P> 0.05). Inflammatory factor: The natural killer cells (NK) and interferon-γ ) Was significantly higher than the control group, IL-10 was significantly lower than the control group (P <0.05); Adverse reactions: the incidence of leukopenia, thrombocytopenia, nausea and vomiting, fatigue in the observation group was significantly lower than the control Group (P <0.05). Conclusion: Pemetrexed combined with Cisplatin can reduce inflammatory reaction, enhance cellular immune function and improve the prognosis of patients with advanced lung adenocarcinoma.